Pfizer Limited (PFIZER) - Total Liabilities
Based on the latest financial reports, Pfizer Limited (PFIZER) has total liabilities worth Rs7.19 Billion INR (≈ $77.75 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore PFIZER shareholders equity momentum to track the company's year-over-year net asset growth rate.
Pfizer Limited - Total Liabilities Trend (2005–2026)
This chart illustrates how Pfizer Limited's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Pfizer Limited to measure how efficiently the company converts operating cash flow to free cash.
Pfizer Limited Competitors by Total Liabilities
The table below lists competitors of Pfizer Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
eToro Group Ltd.
NASDAQ:ETOR
|
USA | $481.88 Million |
|
Bank of Xi'An Co Ltd
SHG:600928
|
China | CN¥506.04 Billion |
|
ACME Solar Holdings Limited
NSE:ACMESOLAR
|
India | Rs156.42 Billion |
|
China Railway Hi-tech Industry Corp Ltd
SHG:600528
|
China | CN¥34.61 Billion |
|
Poco Holding Co Ltd
SHE:300811
|
China | CN¥881.42 Million |
|
KANSAI PAINT SPON.ADR/1/2
F:KAP0
|
Germany | €403.87 Billion |
|
Shanghai Kingstar Winning Software
SHE:300253
|
China | CN¥2.71 Billion |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
USA | $287.74 Million |
Liability Composition Analysis (2005–2026)
This chart breaks down Pfizer Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PFIZER company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.06 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pfizer Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pfizer Limited (2005–2026)
The table below shows the annual total liabilities of Pfizer Limited from 2005 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs7.19 Billion ≈ $77.75 Million |
+3.64% |
| 2025-03-31 | Rs6.94 Billion ≈ $75.02 Million |
+9.55% |
| 2024-03-31 | Rs6.33 Billion ≈ $68.48 Million |
-20.19% |
| 2023-03-31 | Rs7.93 Billion ≈ $85.81 Million |
-23.42% |
| 2022-03-31 | Rs10.36 Billion ≈ $112.05 Million |
+18.70% |
| 2021-03-31 | Rs8.73 Billion ≈ $94.40 Million |
-13.57% |
| 2020-03-31 | Rs10.10 Billion ≈ $109.22 Million |
+8.75% |
| 2019-03-31 | Rs9.29 Billion ≈ $100.43 Million |
-7.76% |
| 2018-03-31 | Rs10.07 Billion ≈ $108.88 Million |
+18.20% |
| 2017-03-31 | Rs8.52 Billion ≈ $92.11 Million |
+7.04% |
| 2016-03-31 | Rs7.96 Billion ≈ $86.05 Million |
+24.62% |
| 2015-03-31 | Rs6.39 Billion ≈ $69.06 Million |
+140.11% |
| 2014-03-31 | Rs2.66 Billion ≈ $28.76 Million |
-27.16% |
| 2013-03-31 | Rs3.65 Billion ≈ $39.48 Million |
+34.34% |
| 2012-03-31 | Rs2.72 Billion ≈ $29.39 Million |
+21.97% |
| 2011-03-31 | Rs2.23 Billion ≈ $24.10 Million |
+6.59% |
| 2010-03-31 | Rs2.09 Billion ≈ $22.61 Million |
+6.35% |
| 2009-03-31 | Rs1.97 Billion ≈ $21.26 Million |
-9.73% |
| 2008-03-31 | Rs2.18 Billion ≈ $23.55 Million |
+5.32% |
| 2007-03-31 | Rs2.07 Billion ≈ $22.36 Million |
+3.32% |
| 2006-03-31 | Rs2.00 Billion ≈ $21.64 Million |
+9.56% |
| 2005-03-31 | Rs1.83 Billion ≈ $19.75 Million |
-- |
About Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more